Aratana Therapeutics
Curated by SignalDeveloper of small molecules and biologics for the various diseases of companion animals
Overview
Developer of small molecules and biologics for the various diseases of companion animals. Its product portfolio includes approximately 18 therapeutic candidates consisting of small molecule pharmaceuticals and biologics. It develops AT-001 to treat the osteoarthritis pain in dogs, and degenerative joint disease in cats; AT-002 for stimulation of appetite in dogs, as well as for weight gain in cats and dogs; AT-003 for the treatment of post-operative pain in cats and dogs; AT-004, a monoclonal antibody (MAB) used in the treatment of B-cell lymphoma in dogs; and AT-005, a canonized MAB for the treatment of T-cell lymphoma in dogs. It also develops other products, such as AT-007 for the treatment of cats infected with the feline immunodeficiency virus.
Key facts
- Founded
- 2009
- Headquarters
- Del Mar, United States
- Stage
- Sign up to view
- Industry
- Health Technology
Contact
- Primary office
- Sign up to view
- Phone
- Sign up to view